Stocks Health care IMNM
NASDAQ · Health careImmunome Inc. (IMNM)
Immunome Inc. brought in $0 of revenue over the twelve months to September 30, 2026, down 100.0% from a year earlier. It posted a net loss of $282.6M. In fiscal 2025 capital spending exceeded operating cash flow by $200.6M. At September 30, 2026 it held $212.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Immunome Inc.
- Net worth
- Immunome Inc. has a market value (market cap) of $2.2B at the latest share price, and shareholders' equity of $454.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $6.9M (-23.2% year on year), with a net loss of $212.4M. Over the 12 months to September 30, 2026: revenue $0, net loss $282.6M.
- Cash flow
- In fiscal 2025 operations used $190.9M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Immunome Inc.'s next report is expected around March 2, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Immunome Inc. does
Immunome Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker IMNM.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $6.9M | -$212.4M | -$2.43 | -$200.6M |
| 2024 | $9M | -$293M | -$5.00 | -$118M |
| 2023 | $14M | -$106.8M | -$5.38 | -$8.4M |
| 2022 | n/a | -$36.9M | -$3.09 | -$28.9M |
| 2021 | n/a | -$24.7M | -$2.14 | -$18.3M |
| 2020 | n/a | -$17.8M | -$5.26 | -$12.7M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where IMNM ranks in Health care
Latest SEC filings
What Immunome Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 9, 2026
- November 9, 2026
- November 9, 2026
- October 30, 2026Passive stake (5% or more) SCHEDULE 13G
- October 5, 2026Material agreement8-KImmunome amended its license agreement with Bristol-Myers Squibb to acquire patent rights and eliminate all future milestone and royalty payments.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 11, 2026
- August 11, 2026
Insider trades
What the people running Immunome Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $334.2K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 11, 2026 | Higgins JackChief Scientific Officer | Exercised options | 18,000 | $24.3K |
| September 11, 2026 | Higgins JackChief Scientific Officer | Soldpre-planned (10b5-1) | 13,200 | $334.2K |
| September 11, 2026 | Higgins JackChief Scientific Officer | Gave as a gift | 8,800 | - |
| August 12, 2026 | Barchas IsaacDirector | Soldpre-planned (10b5-1) | 11,048 | $301.1K |
| August 11, 2026 | Barchas IsaacDirector | Soldpre-planned (10b5-1), indirect | 62,291 | $1.6M |
| August 10, 2026 | Barchas IsaacDirector | Soldpre-planned (10b5-1), indirect | 10,125 | $264K |
| August 7, 2026 | Barchas IsaacDirector | Soldpre-planned (10b5-1), indirect | 15,248 | $397.4K |
| August 6, 2026 | Barchas IsaacDirector | Soldpre-planned (10b5-1), indirect | 20,840 | $543.1K |
Who owns IMNM
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| T. Rowe Price Investment Management, Inc.13G, passive | 17.4% | August 14, 2026 |
| Fmr LLC13G, passive with 1 related filers | 15% | October 7, 2025 |
| Immunome Aggregator, LP13D, may seek influence with 1 related filers | 6% | February 4, 2025 |
| Vanguard Capital Management13G, passive | 5.04% | October 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 202 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 16,987,553 | +17,599 |
| BlackRock, Inc. | 8,805,492 | +636,818 |
| State Street Corp | 5,494,625 | +94,724 |
| Wellington Management Group Llp | 5,210,216 | +478,239 |
| Redmile Group, LLC | 4,911,590 | -647,295 |
| Primecap Management Co | 4,581,431 | -206,800 |
| Vanguard Capital Management LLC | 4,551,289 | +121,592 |
| Driehaus Capital Management LLC | 4,346,139 | +246,238 |
| Enavate Sciences GP, LLC | 3,613,799 | 0 |
| Geode Capital Management, LLC | 2,754,889 | +194,225 |
| Morgan Stanley | 2,407,942 | -433,647 |
| Silverarc Capital Management, LLC | 2,017,009 | +166,731 |
| Jpmorgan Chase & Co | 1,848,548 | -929,288 |
| Sofinnova Investments, Inc. | 1,720,316 | +18,412 |
| Readystate Asset Management LP | 1,605,820 | +303,958 |
| Goldman Sachs Group Inc | 1,512,489 | +411,013 |
| Vanguard Portfolio Management LLC | 1,348,979 | +342,004 |
| Principal Financial Group Inc | 1,347,358 | -29,509 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1,250,275 | +152,439 |
| Woodline Partners LP | 1,000,398 | -575,000 |
Insiders
9 insiders reported holding 1,701,174 shares in total, about $32.9M at the last price.
| Holder | Shares |
|---|---|
| Siegall Clay BPresident and CEO, Director | 870,704 |
| Wagenheim PhilipDirector | 341,147 |
| Rosett MaxChief Financial Officer | 101,287 |
| Barchas IsaacDirector | 92,211 |
| Tsai PhilipChief Technical Officer | 81,550 |
| Lechleider RobertChief Medical Officer | 69,805 |
| Higgins JackChief Scientific Officer | 57,2501,000 held indirectly |
| Stoneman Sandra G.CHIEF LEGAL OFFICER & GC | 43,805 |
| Bienaime Jean JacquesDirector | 43,415 |
Questions about IMNM
What does Immunome Inc. do?
Immunome Inc. is a company in the Health care sector, listed on NASDAQ as IMNM. Its shares trade on NASDAQ under the ticker IMNM.
What is Immunome Inc.'s net worth?
Immunome Inc. has a market value (market cap) of $2.2B at the latest share price, and shareholders' equity of $454.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Immunome Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $282.6M.
How much revenue does Immunome Inc. make?
Over the twelve months to September 30, 2026 Immunome Inc. reported revenue of $0. That is 100.0% less than a year earlier.
When did Immunome Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Immunome Inc.'s next earnings report?
Immunome Inc.'s next report is expected around March 2, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare IMNM with
Follow IMNM
Get an email when Immunome Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Immunome Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.